ImmunoPrecise Begins Path to NASDAQ

This morning ImmunoPrecise Antibodies Ltd (TSXV: IPA) announced they have commenced the application process to dual list their stock on the NASDAQ. In the news release, the company states they believe the move will gain greater exposure for the company to access a larger base of retail and institutional investors in the United States and internationally.

ImmunoPrecise Antibodies Ltd. Logo (CNW Group/ImmunoPrecise Antibodies Ltd.)

ImmunoPrecise is a full-service, therapeutic antibody discovery company utilizing species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe. IPA has developed a technology platform with end-to-end solutions empowering companies to discover and develop therapies against any disease. Their full-service capabilities reduce the time and risk associated with conventional multi-vendor product development.

The company has been working on COVID by identifying antibodies derived from multiple species (human, llama, Ligand’s humanized OmniRat, and wild-type rabbits) which demonstrate potent, in vitro neutralizing activity. They have discovered their functional antibodies using the Company’s DeepDisplay phage technology, B Cell Select and Single Step Hybridoma platforms.

At the time of publishing IPA stock is trading at $1.85 an increase of 3.9%.


Information for this analysis was found via Sedar and ImmunoPrecise Antibodies Ltd. The author is long common shares of ImmunoPrecise Antibodies (IPA.v). Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Why Copper Juniors Could Explode After This Trade War Move | Christian Easterday – Hot Chili

Silver Is Rarer Than Gold, And the Market’s Waking Up | Shawn Khunkhun – Dolly Varden Silver

Gold Will Hit North of $4,000: Who’s Actually Producing? | Shane Williams – West Red Lake

Recommended

ESGold Sees ANT Survey Reveal Vertically Continuous System To 1,200 Metres Depth

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Related News

‘CBD Supports the Immune System’ Austrian Clinic’s Cannabis Trial Suggests Encouraging Results for Covid-19 Patients

According to researchers at the Klagenfurt Clinic in Austria, CBD has shown promising results for...

Saturday, February 6, 2021, 05:14:00 PM

Sona Nanotech Halts COVID-19 Rapid Saliva Test Trials, Drops Research Program

Sona Nanotech (CSE: SONA) this morning had bombshell news, in that it has discontinued its...

Friday, June 11, 2021, 08:58:10 AM

Tesla Stops Nearly All Production at Shanghai Factory Amid Parts Shortages

Tesla (NASDAQ: TSLA) has reportedly suspended nearly all production at its Shanghai factory, after running...

Tuesday, May 10, 2022, 05:04:00 PM

Could There Be a Global Food Shortage? You Betcha’

The COVID-19 pandemic has led to the UN warning the public about the possibility of...

Tuesday, March 31, 2020, 08:33:33 PM

Sona Nanotech Withdraws Health Canada Application For COVID-19 Test Due To Feedback From Regulator

In what is a major blow to shareholders of Sona Nanotech (CSE: SONA), the company...

Wednesday, November 25, 2020, 02:31:06 PM